207 related articles for article (PubMed ID: 28871984)
1. Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.
Jochems A; Deist TM; El Naqa I; Kessler M; Mayo C; Reeves J; Jolly S; Matuszak M; Ten Haken R; van Soest J; Oberije C; Faivre-Finn C; Price G; de Ruysscher D; Lambin P; Dekker A
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):344-352. PubMed ID: 28871984
[TBL] [Abstract][Full Text] [Related]
2. A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Oberije C; De Ruysscher D; Houben R; van de Heuvel M; Uyterlinde W; Deasy JO; Belderbos J; Dingemans AM; Rimner A; Din S; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):935-44. PubMed ID: 25936599
[TBL] [Abstract][Full Text] [Related]
3. Distributed learning: Developing a predictive model based on data from multiple hospitals without data leaving the hospital - A real life proof of concept.
Jochems A; Deist TM; van Soest J; Eble M; Bulens P; Coucke P; Dries W; Lambin P; Dekker A
Radiother Oncol; 2016 Dec; 121(3):459-467. PubMed ID: 28029405
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
5. A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.
Jochems A; El-Naqa I; Kessler M; Mayo CS; Jolly S; Matuszak M; Faivre-Finn C; Price G; Holloway L; Vinod S; Field M; Barakat MS; Thwaites D; de Ruysscher D; Dekker A; Lambin P
Acta Oncol; 2018 Feb; 57(2):226-230. PubMed ID: 29034756
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
[TBL] [Abstract][Full Text] [Related]
8. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
[TBL] [Abstract][Full Text] [Related]
10. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.
Crvenkova S; Pesevska M
J BUON; 2015; 20(3):775-81. PubMed ID: 26214630
[TBL] [Abstract][Full Text] [Related]
11. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
[TBL] [Abstract][Full Text] [Related]
12. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
13. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Dehing-Oberije C; Yu S; De Ruysscher D; Meersschout S; Van Beek K; Lievens Y; Van Meerbeeck J; De Neve W; Rao B; van der Weide H; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):355-62. PubMed ID: 19095367
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Kim YH; Ahn SJ; Kim YC; Kim KS; Oh IJ; Ban HJ; Chung WK; Nam TK; Yoon MS; Jeong JU; Song JY
Jpn J Clin Oncol; 2016 Feb; 46(2):144-51. PubMed ID: 26590014
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
17. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
[TBL] [Abstract][Full Text] [Related]
19. Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.
Siah KW; Khozin S; Wong CH; Lo AW
JCO Clin Cancer Inform; 2019 Sep; 3():1-11. PubMed ID: 31539267
[TBL] [Abstract][Full Text] [Related]
20. Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival.
Ahmed I; Ferro A; Baby R; Malhotra J; Cohler A; Langenfeld J; Aisner J; Zou W; Jabbour SK
J Cancer Res Ther; 2016; 12(2):952-8. PubMed ID: 27461680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
